BCLI vs. ELYM, PLUR, ACRV, SCYX, LTRN, SCLX, LVTX, COEP, MAAQ, and ALGS
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Eliem Therapeutics (ELYM), Pluri (PLUR), Acrivon Therapeutics (ACRV), SCYNEXIS (SCYX), Lantern Pharma (LTRN), Scilex (SCLX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), Mana Capital Acquisition (MAAQ), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs. Its Competitors
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Eliem Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Brainstorm Cell Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 2,531.58%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Eliem Therapeutics.
Brainstorm Cell Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500.
Brainstorm Cell Therapeutics received 282 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 59.03% of users gave Brainstorm Cell Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 0 mentions for Eliem Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.44 beat Eliem Therapeutics' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.
Summary
Brainstorm Cell Therapeutics beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 6/13/2025 by MarketBeat.com Staff
